Research Analysts Issue Forecasts for Harrow Q3 Earnings

Key Points

• B. Riley has reduced its Q3 2025 earnings per share estimate for Harrow, Inc. from $0.36 to $0.33, while maintaining a "Buy" rating and a target price of $74.00.
• Several analysts have raised their target prices on Harrow, with Lake Street Capital increasing its price objective from $42.00 to $70.00, while Zacks Research downgraded the stock's rating from "strong-buy" to "hold".
• Harrow's stock currently has a market capitalization of $1.77 billion, with a 52-week trading range between $20.85 and $59.23.

Harrow, Inc. (NASDAQ:HROW - Free Report) - B. Riley reduced their Q3 2025 earnings per share (EPS) estimates for shares of Harrow in a note issued to investors on Tuesday, September 30th. B. Riley analyst M. Mamtani now anticipates that the company will post earnings of $0.33 per share for the quarter, down from their previous forecast of $0.36. B. Riley currently has a "Buy" rating and a $74.00 target price on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. B. Riley also issued estimates for Harrow's FY2025 earnings at $0.82 EPS, FY2026 earnings at $2.86 EPS and FY2027 earnings at $4.34 EPS.

A number of other analysts have also recently commented on the stock. Lake Street Capital upped their price objective on shares of Harrow from $42.00 to $70.00 and gave the company a "buy" rating in a research report on Monday. Zacks Research cut Harrow from a "strong-buy" rating to a "hold" rating in a report on Friday, September 12th. Craig Hallum increased their target price on Harrow from $54.00 to $64.00 and gave the stock a "buy" rating in a report on Tuesday, September 23rd. William Blair began coverage on shares of Harrow in a research note on Tuesday, June 10th. They set an "outperform" rating for the company. Finally, BTIG Research reiterated a "buy" rating and set a $63.00 price target on shares of Harrow in a report on Wednesday, September 24th. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $68.50.

Harrow Stock Performance

Shares of Harrow stock opened at $47.73 on Friday. The firm has a fifty day moving average of $39.38 and a two-hundred day moving average of $32.07. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of -190.92 and a beta of 0.27. Harrow has a 52 week low of $20.85 and a 52 week high of $59.23. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.58 and a current ratio of 0.62.

Harrow (NASDAQ:HROW - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.01 by $0.23. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%.The business had revenue of $63.74 million for the quarter, compared to the consensus estimate of $64.23 million. Harrow has set its FY 2025 guidance at EPS.

Institutional Trading of Harrow

Several institutional investors have recently modified their holdings of the business. Braidwell LP grew its stake in shares of Harrow by 5.5% in the first quarter. Braidwell LP now owns 956,839 shares of the company's stock worth $25,452,000 after purchasing an additional 49,800 shares during the last quarter. Geode Capital Management LLC boosted its position in Harrow by 4.7% during the second quarter. Geode Capital Management LLC now owns 810,803 shares of the company's stock valued at $24,765,000 after acquiring an additional 36,724 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of Harrow by 31.5% during the second quarter. Marshall Wace LLP now owns 564,876 shares of the company's stock valued at $17,251,000 after purchasing an additional 135,202 shares during the period. Voya Investment Management LLC raised its holdings in shares of Harrow by 4,035.5% during the first quarter. Voya Investment Management LLC now owns 381,461 shares of the company's stock valued at $10,147,000 after purchasing an additional 372,237 shares during the period. Finally, Royce & Associates LP raised its holdings in shares of Harrow by 12.0% during the first quarter. Royce & Associates LP now owns 327,096 shares of the company's stock valued at $8,701,000 after purchasing an additional 35,006 shares during the period. Institutional investors own 72.76% of the company's stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.